Abstract:Objective Through the detection of cellular inflammatory factors, to judge the immune function status of sepsis patients and observe the curative effect of individual application of immunomodulator. Methods A total of 70 sepsis patients who received treatment at Fenyang Hospital, Shanxi Province from January 2019 to December 2020 were selected and divided into observation group (n=42) and control group (n=28). Two patients in the observation group and three patients in the control group who died within 5 days were excluded. Twenty-five patients with sepsis in control group were diagnosed and treated according to Chinese Guidelines for Emergency Treatment of Sepsis/Septic Shock (2018), and 40 patients with sepsis were selected as observation group,whose immune status ［systemic inflammatory response syndrome(SIRS), compensatory anti-inflammatory response syndrome（CARS）, mixed antagonistic response syndrome (MARS)］ were judged by detecting the values of tumor necrosis factor alpha(TNF-α), interleukin（IL)-2R, IL-6, IL-8 and IL-10. In observation group, 10 SIRS patients with mild sepsis were treated with routine anti-infection treatment, 12 SIRS patients with shock were treated with low dose glucocorticoid based on routine treatment, and 18 patients with CARS or MARS were treated with human immunoglobulin based on routine treatment. The values of mean arterial pressure (MAP), heart rate (HR), oxygenation index (PO₂/FiO₂) and blood lactic acid (Lac)before treatment and 12- and 24-hour after treatment, the scores of acute physiology and chronic health evaluation (APACHE-Ⅱ) and sequential organ failure assessment (SOFA) before and 5 days after treatment, the incidence of adverse reactions and 28-day mortality were compared between two groups. Results Before treatment, there was no significant difference in all indexes between two groups (P>0.05). At 12-and 24-hour after treatment, MAP and PO₂/FiO₂ increased, and HR and Lac decreased compared with those before treatment in two groups. With the lapse of time, all indexes improved significantly in both groups,and the improvement was more obvious in observation group than that in control group (P<0.05). After 5 days of treatment, APACHE-Ⅱ and SOFA scores decreased compared with those before treatment in two groups and were lower in observation group than those in control group (P<0.05). There was no significant difference in the incidence of adverse reactions and 28-day mortality between two groups (P>0.05). Conclusion Based on the detection of inflammatory cellular factors for judging the immune function of patients with sepsis, the individual application of immunomodulator can improve the therapeutic effect.